Royce & Associates LP Makes New $11.70 Million Investment in CeriBell, Inc. $CBLL

Royce & Associates LP acquired a new position in shares of CeriBell, Inc. (NASDAQ:CBLL) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 533,300 shares of the company’s stock, valued at approximately $11,695,000.

A number of other hedge funds have also modified their holdings of the company. CWM LLC raised its position in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the period. Tower Research Capital LLC TRC raised its position in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the period. Larson Financial Group LLC raised its position in shares of CeriBell by 1,403.1% in the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock valued at $63,000 after acquiring an additional 2,680 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of CeriBell in the 3rd quarter valued at approximately $33,000. Finally, Sei Investments Co. raised its position in shares of CeriBell by 7.1% in the 3rd quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock valued at $580,000 after acquiring an additional 3,365 shares during the period.

Insider Activity

In other news, CEO Xingjuan Chao sold 6,030 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $18.00, for a total value of $108,540.00. Following the completion of the sale, the chief executive officer owned 830,317 shares of the company’s stock, valued at approximately $14,945,706. This represents a 0.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Raymond Woo sold 1,966 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $35,388.00. Following the completion of the sale, the chief technology officer directly owned 195,682 shares of the company’s stock, valued at approximately $3,522,276. The trade was a 0.99% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 165,300 shares of company stock valued at $3,086,400. 20.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CBLL has been the topic of a number of analyst reports. Canaccord Genuity Group cut their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.

CeriBell Price Performance

Shares of CBLL opened at $18.70 on Thursday. The stock has a market capitalization of $709.48 million, a P/E ratio of -11.47 and a beta of 0.99. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The company has a 50 day moving average of $19.08 and a 200-day moving average of $19.29. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. As a group, equities research analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.